Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02049151 · ClinicalTrials.gov registry record · Phase 3
Tecemotide Following Concurrent Chemo-radiotherapy for Non-small Cell Lung Cancer
A Phase 3 study, sponsored by EMD Serono.
- Terminated
- Registry status
- Phase 3
- Development phase
- 35
- Enrollment target
NCT02049151: Clinical Trial Phase 3 study, sponsored by EMD Serono.
NCT02049151 is a Phase 3 study that was terminated before completion, run by EMD Serono. The registered enrollment target is 35 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02049151, a Phase 3 study, was terminated before completion, sponsored by EMD Serono.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 35 participants
- Enrollment target
Study Summary
This is a multi-center, double-blind, placebo-controlled, randomized, Phase 3 trial in subjects with unresectable stage III non-small cell lung cancer (NSCLC) who have demonstrated either stable disease or objective response following primary concurrent chemo-radiotherapy (CRT), comparing overall survival (OS) time in subjects treated with tecemotide versus subjects treated with tecemotide-matching placebo.
Primary Outcome
Overall survival (OS) was defined as the time (in months) from randomization to death. Data has been presented in terms of number subjects who died and number of censored subjects.
Interventions
- DRUG Placebo
- DRUG Tecemotide
- DRUG Cyclophosphamide (CPA)
- DRUG Saline (sodium chloride)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2014-03 |
| Est. Completion | 2015-07 |
| Phase | Phase 3 |
Why NCT02049151 stopped before completion
NCT02049151 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 35 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT02049151 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02049151 about?
NCT02049151 is a clinical study titled "Tecemotide Following Concurrent Chemo-radiotherapy for Non-small Cell Lung Cancer". This is a multi-center, double-blind, placebo-controlled, randomized, Phase 3 trial in subjects with unresectable stage III non-small cell lung cancer (NSCLC) who have demonstrated either stable disease or objective response following primary concurrent chemo-radiotherapy (CRT), comparing overall su...
What is the current status of trial NCT02049151?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 35 participants. The study started on 2014-03. Estimated completion is 2015-07.
What interventions are being tested in trial NCT02049151?
The interventions under investigation include: Placebo (DRUG), Tecemotide (DRUG), Cyclophosphamide (CPA) (DRUG), Saline (sodium chloride) (DRUG).
Who is sponsoring clinical trial NCT02049151?
This trial is sponsored by EMD Serono, which has 71 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02049151's enrollment target sits among peer trials
35 1903rd of 2000 higher than 96 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01697371 · 35 participants · NA
Proton Therapy in the Treatment of Liver Metastases
- NCT01940757 · 35 participants · Phase 1
Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae
- NCT02235857 · 35 participants · NA
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
- NCT02637934 · 35 participants · Phase 1
Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia